Changes in Nucleolin Expression during Malignant Transformation Leading to Ovarian High-Grade Serous Carcinoma
Objective: Ovarian high-grade serous carcinoma (HGSC) is a fatal malignancy of women. Alterations in the expression of nuclear proteins are early steps in malignant transformation; nucleolin is one such protein. Changes in nucleolin expression and circulatory levels during ovarian HGSC development a...
Saved in:
| Published in | Cancers Vol. 15; no. 3; p. 661 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
21.01.2023
MDPI |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2072-6694 2072-6694 |
| DOI | 10.3390/cancers15030661 |
Cover
| Abstract | Objective: Ovarian high-grade serous carcinoma (HGSC) is a fatal malignancy of women. Alterations in the expression of nuclear proteins are early steps in malignant transformation; nucleolin is one such protein. Changes in nucleolin expression and circulatory levels during ovarian HGSC development are unknown. The study goal was to determine if tissue and circulatory levels of nucleolin change in response to malignant transformation leading to ovarian HGSC. Methods: Sera, ovaries, and BRCA+ fimbria from healthy subjects, and sera and tumor tissues from patients (n = 10 each), and healthy hens and hens with HGSC were examined in exploratory and prospective studies for nucleolin expression by immunohistochemistry, immunoblotting, gene expression, and immunoassay, and analyzed by analysis of variance (ANOVA). Results: Compared with normal, nucleolin expression was higher in patients and hens with ovarian HGSC and in women with a risk of HGSC (P < 0.05). Compared with normal (1400 + 105 pg/mL, n = 8), serum nucleolin levels were 1.5 and 1.7-fold higher in patients with early- (n = 5) and late-stage (n = 5) HGSC, respectively. Additionally, serum nucleolin levels increased significantly (P < 0.05) prior to the formation of detectable masses. Conclusion: This pilot study concluded that tissue and serum levels of nucleolin increase in association with malignant changes in ovaries and fimbriae leading to ovarian HGSC. |
|---|---|
| AbstractList | Ovarian cancer (OVCA) is one of the most fatal gynecologic malignancies with most cases detected in late stages. High mortality rates are due, in part, to the lack of an effective early detection test. Tumor development and progression are associated with an increase in the expression of tissue proteins and/or their release into circulation. These proteins may offer potential markers for the early detection of OVCA. Nucleolin, a nuclear protein, is one such marker. This pilot study examined whether the tissue expression of nucleolin and its serum levels change in association with OVCA development and progression by using archived clinical samples and the laying hen model of spontaneous OVCA. Nucleolin was found to be highly expressed in ovaries and fimbriae with tumors and in serum levels compared to those without OVCA. This study also found that tumor-associated serum levels of nucleolin increase even before the tumor forms a detectable solid mass in the ovary or fimbria, suggesting that nucleolin may be involved in malignant transformation. A smaller sample size is a limitation of this study; however, it will lay the foundation for clinical studies with larger cohorts to examine the efficacy of nucleolin as a potential serum marker for the early detection of OVCA. Objective: Ovarian high-grade serous carcinoma (HGSC) is a fatal malignancy of women. Alterations in the expression of nuclear proteins are early steps in malignant transformation; nucleolin is one such protein. Changes in nucleolin expression and circulatory levels during ovarian HGSC development are unknown. The study goal was to determine if tissue and circulatory levels of nucleolin change in response to malignant transformation leading to ovarian HGSC. Methods: Sera, ovaries, and BRCA+ fimbria from healthy subjects, and sera and tumor tissues from patients (n = 10 each), and healthy hens and hens with HGSC were examined in exploratory and prospective studies for nucleolin expression by immunohistochemistry, immunoblotting, gene expression, and immunoassay, and analyzed by analysis of variance (ANOVA). Results: Compared with normal, nucleolin expression was higher in patients and hens with ovarian HGSC and in women with a risk of HGSC (P < 0.05). Compared with normal (1400 + 105 pg/mL, n = 8), serum nucleolin levels were 1.5 and 1.7-fold higher in patients with early- (n = 5) and late-stage (n = 5) HGSC, respectively. Additionally, serum nucleolin levels increased significantly (P < 0.05) prior to the formation of detectable masses. Conclusion: This pilot study concluded that tissue and serum levels of nucleolin increase in association with malignant changes in ovaries and fimbriae leading to ovarian HGSC. Simple SummaryOvarian cancer (OVCA) is one of the most fatal gynecologic malignancies with most cases detected in late stages. High mortality rates are due, in part, to the lack of an effective early detection test. Tumor development and progression are associated with an increase in the expression of tissue proteins and/or their release into circulation. These proteins may offer potential markers for the early detection of OVCA. Nucleolin, a nuclear protein, is one such marker. This pilot study examined whether the tissue expression of nucleolin and its serum levels change in association with OVCA development and progression by using archived clinical samples and the laying hen model of spontaneous OVCA. Nucleolin was found to be highly expressed in ovaries and fimbriae with tumors and in serum levels compared to those without OVCA. This study also found that tumor-associated serum levels of nucleolin increase even before the tumor forms a detectable solid mass in the ovary or fimbria, suggesting that nucleolin may be involved in malignant transformation. A smaller sample size is a limitation of this study; however, it will lay the foundation for clinical studies with larger cohorts to examine the efficacy of nucleolin as a potential serum marker for the early detection of OVCA.AbstractObjective: Ovarian high-grade serous carcinoma (HGSC) is a fatal malignancy of women. Alterations in the expression of nuclear proteins are early steps in malignant transformation; nucleolin is one such protein. Changes in nucleolin expression and circulatory levels during ovarian HGSC development are unknown. The study goal was to determine if tissue and circulatory levels of nucleolin change in response to malignant transformation leading to ovarian HGSC. Methods: Sera, ovaries, and BRCA+ fimbria from healthy subjects, and sera and tumor tissues from patients (n = 10 each), and healthy hens and hens with HGSC were examined in exploratory and prospective studies for nucleolin expression by immunohistochemistry, immunoblotting, gene expression, and immunoassay, and analyzed by analysis of variance (ANOVA). Results: Compared with normal, nucleolin expression was higher in patients and hens with ovarian HGSC and in women with a risk of HGSC (P < 0.05). Compared with normal (1400 + 105 pg/mL, n = 8), serum nucleolin levels were 1.5 and 1.7-fold higher in patients with early- (n = 5) and late-stage (n = 5) HGSC, respectively. Additionally, serum nucleolin levels increased significantly (P < 0.05) prior to the formation of detectable masses. Conclusion: This pilot study concluded that tissue and serum levels of nucleolin increase in association with malignant changes in ovaries and fimbriae leading to ovarian HGSC. Ovarian cancer (OVCA) is one of the most fatal gynecologic malignancies with most cases detected in late stages. High mortality rates are due, in part, to the lack of an effective early detection test. Tumor development and progression are associated with an increase in the expression of tissue proteins and/or their release into circulation. These proteins may offer potential markers for the early detection of OVCA. Nucleolin, a nuclear protein, is one such marker. This pilot study examined whether the tissue expression of nucleolin and its serum levels change in association with OVCA development and progression by using archived clinical samples and the laying hen model of spontaneous OVCA. Nucleolin was found to be highly expressed in ovaries and fimbriae with tumors and in serum levels compared to those without OVCA. This study also found that tumor-associated serum levels of nucleolin increase even before the tumor forms a detectable solid mass in the ovary or fimbria, suggesting that nucleolin may be involved in malignant transformation. A smaller sample size is a limitation of this study; however, it will lay the foundation for clinical studies with larger cohorts to examine the efficacy of nucleolin as a potential serum marker for the early detection of OVCA. Objective: Ovarian high-grade serous carcinoma (HGSC) is a fatal malignancy of women. Alterations in the expression of nuclear proteins are early steps in malignant transformation; nucleolin is one such protein. Changes in nucleolin expression and circulatory levels during ovarian HGSC development are unknown. The study goal was to determine if tissue and circulatory levels of nucleolin change in response to malignant transformation leading to ovarian HGSC. Methods: Sera, ovaries, and BRCA+ fimbria from healthy subjects, and sera and tumor tissues from patients (n = 10 each), and healthy hens and hens with HGSC were examined in exploratory and prospective studies for nucleolin expression by immunohistochemistry, immunoblotting, gene expression, and immunoassay, and analyzed by analysis of variance (ANOVA). Results: Compared with normal, nucleolin expression was higher in patients and hens with ovarian HGSC and in women with a risk of HGSC (P < 0.05). Compared with normal (1400 + 105 pg/mL, n = 8), serum nucleolin levels were 1.5 and 1.7-fold higher in patients with early- (n = 5) and late-stage (n = 5) HGSC, respectively. Additionally, serum nucleolin levels increased significantly (P < 0.05) prior to the formation of detectable masses. Conclusion: This pilot study concluded that tissue and serum levels of nucleolin increase in association with malignant changes in ovaries and fimbriae leading to ovarian HGSC. Ovarian high-grade serous carcinoma (HGSC) is a fatal malignancy of women. Alterations in the expression of nuclear proteins are early steps in malignant transformation; nucleolin is one such protein. Changes in nucleolin expression and circulatory levels during ovarian HGSC development are unknown. The study goal was to determine if tissue and circulatory levels of nucleolin change in response to malignant transformation leading to ovarian HGSC.OBJECTIVEOvarian high-grade serous carcinoma (HGSC) is a fatal malignancy of women. Alterations in the expression of nuclear proteins are early steps in malignant transformation; nucleolin is one such protein. Changes in nucleolin expression and circulatory levels during ovarian HGSC development are unknown. The study goal was to determine if tissue and circulatory levels of nucleolin change in response to malignant transformation leading to ovarian HGSC.Sera, ovaries, and BRCA+ fimbria from healthy subjects, and sera and tumor tissues from patients (n = 10 each), and healthy hens and hens with HGSC were examined in exploratory and prospective studies for nucleolin expression by immunohistochemistry, immunoblotting, gene expression, and immunoassay, and analyzed by analysis of variance (ANOVA).METHODSSera, ovaries, and BRCA+ fimbria from healthy subjects, and sera and tumor tissues from patients (n = 10 each), and healthy hens and hens with HGSC were examined in exploratory and prospective studies for nucleolin expression by immunohistochemistry, immunoblotting, gene expression, and immunoassay, and analyzed by analysis of variance (ANOVA).Compared with normal, nucleolin expression was higher in patients and hens with ovarian HGSC and in women with a risk of HGSC (P < 0.05). Compared with normal (1400 + 105 pg/mL, n = 8), serum nucleolin levels were 1.5 and 1.7-fold higher in patients with early- (n = 5) and late-stage (n = 5) HGSC, respectively. Additionally, serum nucleolin levels increased significantly (P < 0.05) prior to the formation of detectable masses.RESULTSCompared with normal, nucleolin expression was higher in patients and hens with ovarian HGSC and in women with a risk of HGSC (P < 0.05). Compared with normal (1400 + 105 pg/mL, n = 8), serum nucleolin levels were 1.5 and 1.7-fold higher in patients with early- (n = 5) and late-stage (n = 5) HGSC, respectively. Additionally, serum nucleolin levels increased significantly (P < 0.05) prior to the formation of detectable masses.This pilot study concluded that tissue and serum levels of nucleolin increase in association with malignant changes in ovaries and fimbriae leading to ovarian HGSC.CONCLUSIONThis pilot study concluded that tissue and serum levels of nucleolin increase in association with malignant changes in ovaries and fimbriae leading to ovarian HGSC. Ovarian high-grade serous carcinoma (HGSC) is a fatal malignancy of women. Alterations in the expression of nuclear proteins are early steps in malignant transformation; nucleolin is one such protein. Changes in nucleolin expression and circulatory levels during ovarian HGSC development are unknown. The study goal was to determine if tissue and circulatory levels of nucleolin change in response to malignant transformation leading to ovarian HGSC. Sera, ovaries, and BRCA+ fimbria from healthy subjects, and sera and tumor tissues from patients ( = 10 each), and healthy hens and hens with HGSC were examined in exploratory and prospective studies for nucleolin expression by immunohistochemistry, immunoblotting, gene expression, and immunoassay, and analyzed by analysis of variance (ANOVA). Compared with normal, nucleolin expression was higher in patients and hens with ovarian HGSC and in women with a risk of HGSC ( < 0.05). Compared with normal (1400 + 105 pg/mL, = 8), serum nucleolin levels were 1.5 and 1.7-fold higher in patients with early- ( = 5) and late-stage ( = 5) HGSC, respectively. Additionally, serum nucleolin levels increased significantly ( < 0.05) prior to the formation of detectable masses. This pilot study concluded that tissue and serum levels of nucleolin increase in association with malignant changes in ovaries and fimbriae leading to ovarian HGSC. |
| Audience | Academic |
| Author | Barua, Animesh Basu, Sanjib Bahr, Janice M. Paris, Elizabeth A. |
| AuthorAffiliation | 3 Department of Internal Medicine, Rush University Medical Center, Chicago, IL 60612, USA 1 Department of Anatomy & Cell Biology, Rush University Medical Center, Chicago, IL 60612, USA 4 Department of Pathology, Rush University Medical Center, Chicago, IL 60612, USA 2 Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA 5 Department of Obstetrics and Gynecology, Rush University Medical Center, Chicago, IL 60612, USA |
| AuthorAffiliation_xml | – name: 5 Department of Obstetrics and Gynecology, Rush University Medical Center, Chicago, IL 60612, USA – name: 4 Department of Pathology, Rush University Medical Center, Chicago, IL 60612, USA – name: 1 Department of Anatomy & Cell Biology, Rush University Medical Center, Chicago, IL 60612, USA – name: 3 Department of Internal Medicine, Rush University Medical Center, Chicago, IL 60612, USA – name: 2 Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA |
| Author_xml | – sequence: 1 givenname: Elizabeth A. orcidid: 0000-0002-7594-2954 surname: Paris fullname: Paris, Elizabeth A. – sequence: 2 givenname: Janice M. surname: Bahr fullname: Bahr, Janice M. – sequence: 3 givenname: Sanjib surname: Basu fullname: Basu, Sanjib – sequence: 4 givenname: Animesh surname: Barua fullname: Barua, Animesh |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36765618$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks1v3CAQxVGVqknTnHurLPXSixMMNphLpWiVj0rb5tD0jMaAvUQYtmBH6X8f3CRtsmrhwIj5vYeehrdozwdvEHpf4WNKBT5R4JWJqWowxYxVr9ABwZyUjIl671m9j45SusF5UVpxxt-gfco4a1jVHiC_2oAfTCqsL77NypngcnV2t40mJRt8oedo_VB8BWcHD34qriP41Ic4wrT01wb0AkyhuLqFaMEXl3bYlBcRtCm-mxjmVKwgKuvDCO_Q6x5cMkeP5yH6cX52vbos11cXX1an61LVbTuVoKGhVJG2qwE6DJoIoUldY0WZakgtOCYCK2KaThHNhelarLjucEV5z3hFD9HnB9_t3I1GK-OnCE5uox0h_pIBrHzZ8XYjh3ArhagoZYvBp0eDGH7OJk1ytEkZ58CbnEgSzhtGGt7yjH7cQW_CHH2Ot1A5T81b-pcawBlpfR_yu2oxlae8phiLlpNMHf-Dylub0ao8_t7m-xeCD8-D_kn4NOEMNA-AiiGlaHqp7PR7dNnZOllhuXwmufOZsu5kR_dk_T_FPQPNzTc |
| CitedBy_id | crossref_primary_10_1016_j_pbiomolbio_2025_01_002 crossref_primary_10_3390_cancers15215300 |
| Cites_doi | 10.1016/0014-4827(89)90243-7 10.18632/oncotarget.14779 10.1074/jbc.M112.349274 10.1007/s10637-013-0045-6 10.1002/ijc.28582 10.2174/1574892808666131119095953 10.1371/journal.pone.0255007 10.1093/ajcp/111.2.267 10.1038/onc.2014.22 10.2214/AJR.15.15199 10.1126/science.aad7297 10.1056/NEJMcp0901926 10.1016/j.semcancer.2020.12.024 10.1038/nrc3535 10.1111/j.1600-0897.2005.00287.x 10.1073/pnas.84.6.1472 10.1016/j.yexcr.2018.06.005 10.1593/tlo.12184 10.1111/bph.14830 10.1007/s12032-017-1026-y 10.1177/0161734614553603 10.1097/IGC.0000000000000040 10.1158/1940-6207.CAPR-19-0184 10.1016/0145-2126(84)90135-8 10.1182/blood-2012-12-471094 10.1038/s41467-018-06606-2 10.1155/2022/2870389 10.1001/jama.2017.21421 10.1038/nature07205 10.1007/978-1-4899-8032-8_20 10.1016/j.lfs.2017.07.025 10.2353/ajpath.2010.081063 10.1038/s41598-017-09353-4 10.1186/s13000-014-0175-y 10.1126/science.aan2507 10.1016/j.febslet.2014.03.047 10.1007/s12031-014-0375-7 10.1042/CBI20100625 10.1016/j.ajog.2013.12.041 10.15537/smj.2016.12.15972 10.1158/0008-5472.CAN-16-0300 10.1155/2015/567459 10.1111/IGC.0b013e3181a41613 10.1006/gyno.2001.6191 10.1016/j.ccr.2013.10.013 10.1146/annurev-animal-021419-084001 10.1007/s12032-015-0530-1 10.1016/j.clgc.2016.12.004 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2023 MDPI AG 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023 by the authors. 2023 |
| Copyright_xml | – notice: COPYRIGHT 2023 MDPI AG – notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023 by the authors. 2023 |
| DBID | AAYXX CITATION NPM 3V. 7T5 7TO 7XB 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ GUQSH H94 HCIFZ LK8 M2O M7P MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.3390/cancers15030661 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Immunology Abstracts Oncogenes and Growth Factors Abstracts ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Biological Sciences Research Library Biological Science Database Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2072-6694 |
| ExternalDocumentID | PMC9913361 A743009872 36765618 10_3390_cancers15030661 |
| Genre | Journal Article |
| GeographicLocations | United States St Louis Missouri United States--US |
| GeographicLocations_xml | – name: United States – name: St Louis Missouri – name: United States--US |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA210370 – fundername: National Institutes of Health grantid: R01 CA210370 – fundername: NIH/NCI grantid: CA210370 |
| GroupedDBID | --- 53G 5VS 8FE 8FH 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO E3Z EBD ESX GNUQQ GUQSH GX1 HCIFZ HYE IAO IHR ITC KQ8 LK8 M2O M48 M7P MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS 3V. GROUPED_DOAJ NPM PMFND 7T5 7TO 7XB 8FK H94 MBDVC PKEHL PQEST PQGLB PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c488t-ada533c28b4aab0ad299d2440c36c524970290c2e5bc2d79eb80c7db0137f6713 |
| IEDL.DBID | M48 |
| ISSN | 2072-6694 |
| IngestDate | Thu Aug 21 18:38:20 EDT 2025 Fri Sep 05 03:14:06 EDT 2025 Fri Jul 25 11:52:44 EDT 2025 Tue Jun 17 22:20:04 EDT 2025 Tue Jun 10 21:22:20 EDT 2025 Thu Jan 02 22:54:14 EST 2025 Thu Apr 24 23:00:20 EDT 2025 Tue Jul 01 01:21:10 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | ultrasound imaging fimbria ovarian cancer serum marker chicken model early detection nucleolin |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c488t-ada533c28b4aab0ad299d2440c36c524970290c2e5bc2d79eb80c7db0137f6713 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-7594-2954 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/cancers15030661 |
| PMID | 36765618 |
| PQID | 2774884783 |
| PQPubID | 2032421 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9913361 proquest_miscellaneous_2775625787 proquest_journals_2774884783 gale_infotracmisc_A743009872 gale_infotracacademiconefile_A743009872 pubmed_primary_36765618 crossref_citationtrail_10_3390_cancers15030661 crossref_primary_10_3390_cancers15030661 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20230121 |
| PublicationDateYYYYMMDD | 2023-01-21 |
| PublicationDate_xml | – month: 1 year: 2023 text: 20230121 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Cancers |
| PublicationTitleAlternate | Cancers (Basel) |
| PublicationYear | 2023 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Hughes (ref_7) 1999; 111 Wise (ref_37) 2013; 121 Barua (ref_48) 2015; 37 Koutsioumpa (ref_45) 2014; 9 Hsu (ref_42) 2015; 34 Qiu (ref_40) 2015; 32 Jia (ref_34) 2017; 186 Watanabe (ref_41) 2014; 134 ref_15 Ghoneum (ref_3) 2021; 77 Trinidad (ref_43) 2020; 13 Zuber (ref_26) 1989; 182 Henderson (ref_4) 2018; 319 Wu (ref_39) 2014; 588 Barnes (ref_18) 2001; 81 Shin (ref_38) 2018; 9 Denais (ref_32) 2014; 773 ref_21 Barua (ref_20) 2022; 10 Yellapa (ref_22) 2014; 210 Barua (ref_23) 2012; 5 Zhang (ref_16) 2017; 357 Luborsky (ref_8) 2005; 54 Javadi (ref_2) 2016; 206 Wang (ref_35) 2011; 35 Barua (ref_17) 2009; 19 Denais (ref_44) 2016; 352 Lapeyre (ref_28) 1987; 84 Barua (ref_49) 2014; 24 Carmo (ref_12) 2018; 370 Perets (ref_1) 2013; 24 Johnson (ref_19) 2013; 13 Rosenberg (ref_46) 2014; 32 Kumar (ref_30) 2017; 7 (ref_5) 2009; 361 Tulchin (ref_11) 2010; 176 Chen (ref_9) 2016; 37 Capriglione (ref_6) 2017; 34 Mongelard (ref_47) 2010; 12 Ramirez (ref_24) 2022; 2022 Celis (ref_25) 1984; 8 Guo (ref_14) 2014; 9 Mantovani (ref_33) 2008; 454 Lv (ref_31) 2015; 55 Chalfin (ref_10) 2017; 15 Gilles (ref_13) 2016; 76 Chen (ref_29) 2012; 287 Barua (ref_50) 2015; 2015 Blok (ref_27) 2017; 8 Mariero (ref_36) 2019; 176 |
| References_xml | – volume: 182 start-page: 384 year: 1989 ident: ref_26 article-title: Quantitation and subcellular localization of proliferating cell nuclear antigen (PCNA/cyclin) in oocytes and eggs of Xenopus laevis publication-title: Exp. Cell Res. doi: 10.1016/0014-4827(89)90243-7 – volume: 8 start-page: 15610 year: 2017 ident: ref_27 article-title: Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer publication-title: Oncotarget doi: 10.18632/oncotarget.14779 – volume: 287 start-page: 16467 year: 2012 ident: ref_29 article-title: Interactions of nucleolin and ribosomal protein L26 (RPL26) in translational control of human p53 mRNA publication-title: J. Biol. Chem. doi: 10.1074/jbc.M112.349274 – volume: 32 start-page: 178 year: 2014 ident: ref_46 article-title: A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma publication-title: Investig. New Drugs doi: 10.1007/s10637-013-0045-6 – volume: 134 start-page: 2373 year: 2014 ident: ref_41 article-title: Epithelial-mesenchymal transition in human gastric cancer cell lines induced by TNF-alpha-inducing protein of Helicobacter pylori publication-title: Int. J. Cancer doi: 10.1002/ijc.28582 – volume: 9 start-page: 137 year: 2014 ident: ref_45 article-title: Cell surface nucleolin as a target for anti-cancer therapies publication-title: Recent Pat. Anti-Cancer Drug Discov. doi: 10.2174/1574892808666131119095953 – ident: ref_21 doi: 10.1371/journal.pone.0255007 – volume: 111 start-page: 267 year: 1999 ident: ref_7 article-title: Nuclear matrix proteins and their potential applications to diagnostic pathology publication-title: Am. J. Clin. Pathol. doi: 10.1093/ajcp/111.2.267 – volume: 34 start-page: 826 year: 2015 ident: ref_42 article-title: MMP7-mediated cleavage of nucleolin at Asp255 induces MMP9 expression to promote tumor malignancy publication-title: Oncogene doi: 10.1038/onc.2014.22 – volume: 206 start-page: 1351 year: 2016 ident: ref_2 article-title: Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging publication-title: Am. J. Roentgenol. doi: 10.2214/AJR.15.15199 – volume: 352 start-page: 353 year: 2016 ident: ref_44 article-title: Nuclear envelope rupture and repair during cancer cell migration publication-title: Science doi: 10.1126/science.aad7297 – volume: 361 start-page: 170 year: 2009 ident: ref_5 article-title: Clinical practice. Screening for ovarian cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMcp0901926 – volume: 77 start-page: 83 year: 2021 ident: ref_3 article-title: Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2020.12.024 – volume: 13 start-page: 432 year: 2013 ident: ref_19 article-title: The hen as a model of ovarian cancer publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3535 – volume: 54 start-page: 55 year: 2005 ident: ref_8 article-title: Anti-tumor antibodies in ovarian cancer publication-title: Am. J. Reprod. Immunol. doi: 10.1111/j.1600-0897.2005.00287.x – volume: 84 start-page: 1472 year: 1987 ident: ref_28 article-title: Nucleolin, the major nucleolar protein of growing eukaryotic cells: An unusual protein structure revealed by the nucleotide sequence publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.84.6.1472 – volume: 370 start-page: 68 year: 2018 ident: ref_12 article-title: Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity publication-title: Exp. Cell Res. doi: 10.1016/j.yexcr.2018.06.005 – volume: 5 start-page: 260 year: 2012 ident: ref_23 article-title: Expression of death receptor 6 by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer publication-title: Transl. Oncol. doi: 10.1593/tlo.12184 – volume: 176 start-page: 4360 year: 2019 ident: ref_36 article-title: Inhibiting nucleolin reduces inflammation induced by mitochondrial DNA in cardiomyocytes exposed to hypoxia and reoxygenation publication-title: Br. J. Pharmacol. doi: 10.1111/bph.14830 – volume: 34 start-page: 164 year: 2017 ident: ref_6 article-title: Ovarian cancer recurrence and early detection: May HE4 play a key role in this open challenge? A systematic review of literature publication-title: Med. Oncol. doi: 10.1007/s12032-017-1026-y – volume: 37 start-page: 224 year: 2015 ident: ref_48 article-title: VEGFR2-Targeted Ultrasound Imaging Agent Enhances the Detection of Ovarian Tumors at Early Stage in Laying Hens, a Preclinical Model of Spontaneous Ovarian Cancer publication-title: Ultrason. Imaging doi: 10.1177/0161734614553603 – volume: 24 start-page: 19 year: 2014 ident: ref_49 article-title: Enhancement of ovarian tumor detection with alphavbeta3 integrin-targeted ultrasound molecular imaging agent in laying hens: A preclinical model of spontaneous ovarian cancer publication-title: Int. J. Gynecol. Cancer doi: 10.1097/IGC.0000000000000040 – volume: 13 start-page: 241 year: 2020 ident: ref_43 article-title: Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers publication-title: Cancer Prev. Res. doi: 10.1158/1940-6207.CAPR-19-0184 – volume: 8 start-page: 143 year: 1984 ident: ref_25 article-title: Cyclin: A nuclear protein whose level correlates directly with the proliferative state of normal as well as transformed cells publication-title: Leuk. Res. doi: 10.1016/0145-2126(84)90135-8 – volume: 121 start-page: 4729 year: 2013 ident: ref_37 article-title: Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex publication-title: Blood doi: 10.1182/blood-2012-12-471094 – volume: 9 start-page: 4113 year: 2018 ident: ref_38 article-title: Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway publication-title: Nat. Commun. doi: 10.1038/s41467-018-06606-2 – volume: 2022 start-page: 2870389 year: 2022 ident: ref_24 article-title: Changes in IL-16 Expression in the Ovary during Aging and Its Potential Consequences to Ovarian Pathology publication-title: J. Immunol. Res. doi: 10.1155/2022/2870389 – volume: 12 start-page: 107 year: 2010 ident: ref_47 article-title: AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia publication-title: Curr. Opin. Mol. Ther. – volume: 319 start-page: 595 year: 2018 ident: ref_4 article-title: Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force publication-title: Jama doi: 10.1001/jama.2017.21421 – volume: 454 start-page: 436 year: 2008 ident: ref_33 article-title: Cancer-related inflammation publication-title: Nature doi: 10.1038/nature07205 – volume: 773 start-page: 435 year: 2014 ident: ref_32 article-title: Nuclear mechanics in cancer publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-1-4899-8032-8_20 – volume: 186 start-page: 1 year: 2017 ident: ref_34 article-title: New perspectives of physiological and pathological functions of nucleolin (NCL) publication-title: Life Sci. doi: 10.1016/j.lfs.2017.07.025 – volume: 176 start-page: 1203 year: 2010 ident: ref_11 article-title: BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines publication-title: Am. J. Pathol. doi: 10.2353/ajpath.2010.081063 – volume: 7 start-page: 9017 year: 2017 ident: ref_30 article-title: Integrated analysis of mRNA and miRNA expression in HeLa cells expressing low levels of Nucleolin publication-title: Sci. Rep. doi: 10.1038/s41598-017-09353-4 – volume: 9 start-page: 175 year: 2014 ident: ref_14 article-title: Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy publication-title: Diagn. Pathol. doi: 10.1186/s13000-014-0175-y – volume: 357 start-page: eaan2507 year: 2017 ident: ref_16 article-title: A pathology atlas of the human cancer transcriptome publication-title: Science doi: 10.1126/science.aan2507 – volume: 588 start-page: 1921 year: 2014 ident: ref_39 article-title: Phosphorylation and changes in the distribution of nucleolin promote tumor metastasis via the PI3K/Akt pathway in colorectal carcinoma publication-title: FEBS Lett. doi: 10.1016/j.febslet.2014.03.047 – volume: 55 start-page: 519 year: 2015 ident: ref_31 article-title: Cell surface protein C23 affects EGF-EGFR induced activation of ERK and PI3K-AKT pathways publication-title: J. Mol. Neurosci. doi: 10.1007/s12031-014-0375-7 – volume: 35 start-page: 677 year: 2011 ident: ref_35 article-title: Cell-surface nucleolin is involved in lipopolysaccharide internalization and signalling in alveolar macrophages publication-title: Cell Biol. Int. doi: 10.1042/CBI20100625 – volume: 210 start-page: 272.e1 year: 2014 ident: ref_22 article-title: Interleukin 16 expression changes in association with ovarian malignant transformation publication-title: Am. J. Obstet. Gynecol. doi: 10.1016/j.ajog.2013.12.041 – volume: 37 start-page: 1312 year: 2016 ident: ref_9 article-title: Roles of nucleolin. Focus on cancer and anti-cancer therapy publication-title: Saudi Med. J. doi: 10.15537/smj.2016.12.15972 – volume: 76 start-page: 7181 year: 2016 ident: ref_13 article-title: Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-0300 – volume: 2015 start-page: 567459 year: 2015 ident: ref_50 article-title: Interleukin 16- (IL-16-) Targeted Ultrasound Imaging Agent Improves Detection of Ovarian Tumors in Laying Hens, a Preclinical Model of Spontaneous Ovarian Cancer publication-title: Biomed Res. Int. doi: 10.1155/2015/567459 – volume: 19 start-page: 531 year: 2009 ident: ref_17 article-title: Histopathology of ovarian tumors in laying hens: A preclinical model of human ovarian cancer publication-title: Int. J. Gynecol. Cancer doi: 10.1111/IGC.0b013e3181a41613 – ident: ref_15 – volume: 81 start-page: 373 year: 2001 ident: ref_18 article-title: Immunohistochemical expression of molecular markers in an avian model: A potential model for preclinical evaluation of agents for ovarian cancer chemoprevention publication-title: Gynecol. Oncol. doi: 10.1006/gyno.2001.6191 – volume: 24 start-page: 751 year: 2013 ident: ref_1 article-title: Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models publication-title: Cancer Cell doi: 10.1016/j.ccr.2013.10.013 – volume: 10 start-page: 241 year: 2022 ident: ref_20 article-title: Ovarian Cancer: Applications of Chickens to Humans publication-title: Annu. Rev. Anim. Biosci. doi: 10.1146/annurev-animal-021419-084001 – volume: 32 start-page: 75 year: 2015 ident: ref_40 article-title: The involvement of cell surface nucleolin in the initiation of CCR6 signaling in human hepatocellular carcinoma publication-title: Med. Oncol. doi: 10.1007/s12032-015-0530-1 – volume: 15 start-page: e477 year: 2017 ident: ref_10 article-title: Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells publication-title: Clin. Genitourin. Cancer doi: 10.1016/j.clgc.2016.12.004 |
| SSID | ssj0000331767 |
| Score | 2.3029814 |
| Snippet | Objective: Ovarian high-grade serous carcinoma (HGSC) is a fatal malignancy of women. Alterations in the expression of nuclear proteins are early steps in... Ovarian high-grade serous carcinoma (HGSC) is a fatal malignancy of women. Alterations in the expression of nuclear proteins are early steps in malignant... Ovarian cancer (OVCA) is one of the most fatal gynecologic malignancies with most cases detected in late stages. High mortality rates are due, in part, to the... Simple SummaryOvarian cancer (OVCA) is one of the most fatal gynecologic malignancies with most cases detected in late stages. High mortality rates are due, in... |
| SourceID | pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 661 |
| SubjectTerms | Antibodies Ascites Breast cancer Cancer Carcinoma Euthanasia Gene expression Genetic aspects Genetic transformation Health aspects Histopathology Immunoblotting Immunohistochemistry Laboratories Malignancy Nucleolin Ovarian cancer Pathology Pili Proteins Serum levels Software Tumors |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB6VrYS4IN4ECjISElxME-fh5IBQqbZUiF0QaqXeIsfOlkrglN0t4ufzzebBphKcx4kcjz3zjTPzDdHL2LnURYWWaeS0hMdTskgWVprFwhW5hUPJuTh5Ns-OT5OPZ-nZDs37WhhOq-xt4sZQu8byHfm-Ak7JYUrz-N3lT8ldo_jvat9Cw3StFdzbDcXYDdqFSU7DCe2-n86_fB1uXcIY_jLTLcdPjHh_3_LiLlfARQDPWTRyT9eN9JaXGmdQbrmkozt0u8OS4qBV_l3aqf09ujnr_pbfJ9-WDqzEhRdz5i3mBj1i-rvLffWirVEUM2Dxc06IESdbMBbyT22GvVg34vMvBNXGC84LkR-WxtUCZqa5WolD7kbkmx_mAZ0eTU8Oj2XXX0FaLOVaGmcA9qzKq8SYKjQOrslBO6GNM5siLtOhKkKr6rSyyumirvLQasc3p3qRIbp9SBPf-PoxCZOZKNLWQJ4k2gFnpGGCoD3RNSyCNQG96Ze1tB35OPfA-F4iCGE9lNf0ENDr4YHLlnfj30NfsZ5KPpF4pzVdYQFmxtxW5QFAEtOmahXQ3mgkTpIdi3tNl91JXpV_911ALwYxP8nZab7GQvMYjiPxpQE9ajfGMGlmxANGzQPSoy0zDGB-77HEX3zb8HwDusdxFj35_7Se0i0F4MXXQirao8l6eVU_A1BaV8-73f8HbMMVsA priority: 102 providerName: ProQuest |
| Title | Changes in Nucleolin Expression during Malignant Transformation Leading to Ovarian High-Grade Serous Carcinoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36765618 https://www.proquest.com/docview/2774884783 https://www.proquest.com/docview/2775625787 https://pubmed.ncbi.nlm.nih.gov/PMC9913361 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwED7BJiFeEL8JjMpISPDikTg_nDwgNKZuE6IFoVXqW-TYKUwaLrQdGv893yVpaabB89mW4zv7vi8-3xG9jJ1LXVRomUZOS3g8JYtkZqWZzVyRWziUnB8nj8bZyST5ME2nf8sBdQu4vJbacT2pyeJ8__Ln73fY8G-ZcYKyv7G8PosloA3wL1Oh3eayiOP4OqzfHMsxXGVTUVaFWsksK5I21c91Y_S81NWzestZ9QMptzzT0V2600FKcdDawD26Ufv7dGvUXZo_IN--IFiKMy_GnL6Y6_SI4WUXAutF-1RRjADJv3JcjDjdQrOQf2wD7cVqLj79Arc2XnB4iDxeGFcLnDbzi6U45KJEfv7dPKTJ0fD08ER2ZRakxe5dSeMMMJ9VeZUYU4XGwUM5KCm0cWZT0DMdqiK0qk4rq5wu6ioPrXb8A1XPMpDcR7Tj575-QsJkJoq0NZAniXaAG2mYgLsnusbBYE1A--tlLW2Xg5xLYZyX4CKsh_KKHgJ6venwo02_8e-mr1hPJZsKxrSme1-AmXGKq_IAWImzp2oV0F6vJTaU7YvXmi7X9lgqwOQcnjyPA3qxEXNPDlLzNRaa2zCdxJcG9Lg1jM2kOTEeoGoekO6ZzKYBp_nuS_zZtybdNxB8HGfR0__P-hndVsBf_HdIRXu0s1pc1M-Bl1bVgHbfD8efvwzo5vE0GjS74g8f2Bb3 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQS9IN4NFDASCC5pE-fh5FChUrZs6e6C0FbqLTi2FyqBUzZbHn-O38bMxlk2leDW8ziW47FnvhnPA-BppHWiw1z4SaiFjxqP-3k8Vb6cTnWeKVQoGSUnj8bp4Dh-e5KcrMHvNheGwipbmbgQ1LpS5CPf4YhTMhSlWfTy7JtPXaPodbVtoSFdawW9uygx5hI7jsyvH2jC1buHr5Hfzzg_6E_2B77rMuArnHDuSy0R8iielbGUZSA1CmiNawxUlKoErRMR8DxQ3CSl4lrkpswCJTT5D8U0RRsP570C6zE5UHqw_qo_fv9h6eUJItTPqWhqCkVRHuwoYuasRhyGYD0NO-rwolJY0YrdiM0VFXhwA6477Mr2msN2E9aMvQVXR-51_jbYJlWhZqeWjalOMjUEYv2fLtbWsiYnko0Q-3-iABw2WYHNSB82Ef1sXrF339GIl5ZRHIr_Zia1YSjWqvOa7VP3I1t9lXfg-FJ2-i70bGXNJjCZyjAUSiI9joVGXJMEsSl5LAxKICU92G63tVCu2Dn13PhSoNFDfCgu8MGDF8sPzpo6H_8e-pz4VJAEwDmVdIkMuDKqpVXsISijMq2Ce7DVGYk3V3XJLacLJznq4u859-DJkkxfUjScNbjRNIbsVvxTD-41B2O5aKrAh5g480B0jsxyANUT71Ls6edFXXE0FaIoDe__f1mP4dpgMhoWw8Px0QPY4Aj6yCXFwy3ozWfn5iGCtHn5yN0EBh8v-_L9AaKcUj0 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VVqq4IN4EChgJBJewifNwcqhQaXdpaXepUCv1ljq2FyqBUzZbHn-RX8XMxgmbSnDr2Y7leOyZb-yZbwCeR1onOsyFn4Ra-GjxuJ_HU-XL6VTnmUKDklFy8niS7h7H70-SkxX43ebCUFhlqxMXilpXiu7IBxxxSoaqNIsGUxcWcbgzenP-zacKUvTS2pbTkK7Mgt5c0I25JI998-sHunP15t4Oyv4F56Ph0fau7yoO-AoHn_tSS4Q_imdlLGUZSI3KWuN8AxWlKkFPRQQ8DxQ3Sam4Frkps0AJTXeJYpqiv4fjXoM1gVYfHcG1t8PJ4cfuxieI0FanouEXiqI8GCgS7KxGTIbAPQ17pvGygViykP3ozSVzOLoJNxyOZVvNxrsFK8behvWxe6m_A7ZJW6jZmWUT4kym4kBs-NPF3VrW5EeyMfoBnygYhx0tQWhsP2ii-9m8Yh--o0MvLaOYFP_dTGrDUMVVFzXbpkpItvoq78Lxlaz0PVi1lTUPgMlUhqFQEtvjWGjEOEkQm5LHwqA2UtKD1-2yFsoRn1P9jS8FOkAkh-KSHDx41X1w3nB-_LvrS5JTQdoAx1TSJTXgzIhXq9hCgEaUrYJ7sNHriadY9ZtbSRdOi9TF3z3vwbOumb6kyDhrcKGpD_mw-Kce3G82RjdpYuNDfJx5IHpbputA3OL9Fnv2ecExjm5DFKXhw_9P6yms4yEsDvYm-4_gOkf8R7dTPNyA1fnswjxGvDYvn7iDwOD0qs_eH2y5VoE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Changes+in+Nucleolin+Expression+during+Malignant+Transformation+Leading+to+Ovarian+High-Grade+Serous+Carcinoma&rft.jtitle=Cancers&rft.au=Paris%2C+Elizabeth+A&rft.au=Bahr%2C+Janice+M&rft.au=Basu%2C+Sanjib&rft.au=Barua%2C+Animesh&rft.date=2023-01-21&rft.pub=MDPI+AG&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=15&rft.issue=3&rft_id=info:doi/10.3390%2Fcancers15030661&rft.externalDocID=A743009872 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon |